Challenges in recognizing treatment-related neuroendocrine prostate cancer

Journal of Clinical Oncology

Volumn 30, Issue 36, 2012, Pages

  Beltran, Himisha ^a   Tagawa, Scott T ^a   Park, Kyung ^a   MacDonald, Theresa ^a   Milowsky, Matthew I ^b   Mosquera, Juan Miguel ^a   Rubin, Mark A ^a   Nanus, David M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DYSPNEA; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LIVER BIOPSY; LIVER METASTASIS; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE PROSTATE CANCER; NEUROENDOCRINE TUMOR; PLEURA BIOPSY; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS;

EID: 84871610394     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.5166     Document Type: Article

References (15)

1. Palmgren JS, Karavadia SS, Wakefield MR: Unusual and underappreciated: Small cell carcinoma of the prostate. Semin Oncol 34:22-29, 2007
2. Hirano D, Okada Y, Minei S, et al: Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45:586-592, discussion 592, 2004
3. Berruti A, Mosca A, Porpiglia F, et al: Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol 178:838-843, quiz 1129, 2007
4. Beltran H, Rickman DS, Park K, et al: Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discovery 1:487-495, 2011
5. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
6. Knudsen KE, Scher HI: Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 15:4792-4798, 2009
7. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
8. Beltran H, Beer TM, Carducci MA, et al: New therapies for castration-resistant prostate cancer: Efficacy and safety. Eur Urol 60:279-290, 2011
9. Aparicio A, Logothetis CJ, Maity SN: Understanding the lethal variant of prostate cancer: Power of examining extremes. Cancer Discovery 1:466-468, 2011
10. Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648, 2005
11. Lotan TL, Gupta NS, Wang W, et al: ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 24:820-828, 2011
12. Scheble VJ, Braun M, Wilbertz T, et al: ERG rearrangement in small cell prostatic and lung cancer. Histopathology 56:937-943, 2010
13. Scheble VJ, Braun M, Beroukhim R, et al: ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 23:1061-1067, 2010
14. Rubin MA, Maher CA, Chinnaiyan AM: Common gene rearrangements in prostate cancer. J Clin Oncol 29:3659-3668, 2011
15. Papandreou CN, Daliani DD, Thall PF, et al: Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20:3072-3080, 2002